"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
| Descriptor ID |
D001500
|
| MeSH Number(s) |
D20.215.894.135.825.100
|
| Concept/Terms |
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
|
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 2 | 5 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Prevention of tuberculosis in cynomolgus macaques by an attenuated Mycobacterium tuberculosis vaccine candidate. Nat Commun. 2025 Feb 25; 16(1):1957.
-
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.
-
BCG vaccination alters the epigenetic landscape of progenitor cells in human bone marrow to influence innate immune responses. Immunity. 2024 09 10; 57(9):2095-2107.e8.
-
Alendronate modulates cytokine responses in healthy young individuals after BCG vaccination. Immunol Lett. 2024 06; 267:106851.
-
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. Urol Oncol. 2024 Aug; 42(8):223-228.
-
Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice. Hum Vaccin Immunother. 2024 12 31; 20(1):2302070.
-
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563.
-
Lung Epithelial Signaling Mediates Early Vaccine-Induced CD4+ T Cell Activation and Mycobacterium tuberculosis Control. mBio. 2021 08 31; 12(4):e0146821.
-
Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nat Immunol. 2021 01; 22(1):2-6.
-
SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020 Dec; 65(12):1075-1082.